About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Investor Centre
- Investor Centre
- News & ASX Announcements
Contact

Hit enter to search or ESC to close

Voluntary Withdrawal from OTCQX

December 3, 2018

Click here to read more

Post navigation

Receipt of R&D Tax Incentive

Phosphagenics and Mylan Agree Settlement

Related Posts

Phosphagenics Signs Japanese License Option Agreement and R&D Alliance

April 29, 2016

Phosphagenics Announces Equity Raising

September 26, 2017

Ethics Approval to Commence Topical TPM®/Oxycodone Patch Trial

December 8, 2014

Recent Posts

Ashland Purchases Manufacturing Rights for VitalET and TPM
June 20, 2019
Change of Company Name and ASX Code
May 24, 2019
2019 Annual General Meeting Results
May 22, 2019

Categories

Analyst Coverage
Company Announcement
Company Report
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- News & ASX Announcements

© Copyright 2019 Avecho Biotechnology Ltd.